Chief Financial Officer Aradhana Sarin reported that AstraZeneca achieved total revenue growth of 11% and core EPS expansion of 15% over the first nine months of 2025. Oncology led therapy-area gains with a 16% increase, biopharmaceuticals rose 8% and rare disease climbed 6%, driven by newer medicines offsetting losses of exclusivity on mature brands such as Brilinta, Pulmicort and Soliris. Regionally, the U.S. delivered 11% growth while emerging markets outside China surged 21%. Management reaffirmed guidance for high single-digit revenue growth and low double-digit core EPS expansion at constant exchange rates, though flagged fourth-quarter headwinds from volume-based procurement in China and the timing of emerging-market tenders, as well as a tougher year-on-year comparison due to over $800 million of collaboration milestones recognized in Q4 2024. Full-year results are scheduled for Feb. 10.

Sarin described 2025 as a "catalyst-rich year," with AstraZeneca delivering 16 positive Phase III readouts representing peak revenue opportunities exceeding $10 billion. Late in the year, the FDA approved Imfinzi for perioperative gastric cancer and Enhertu for first-line HER2-positive breast cancer, and accepted baxdrostat for priority review in hypertension. Looking ahead, the company plans multiple 2026 launches, including baxdrostat, the oral aldosterone synthase inhibitor; camizestrant, its novel estrogen receptor degrader; and garadacimab, its anti-plasma kallikrein antibody, all under regulatory review.

AstraZeneca maintains a science-driven R&D governance model without pre-allocating budgets by therapy area, prioritizing projects via a collective decision framework. Full-year 2026 R&D spending is forecast toward the upper end of the low-20% range of revenue to support 104 ongoing Phase III studies and a large anticipated patient-enrollment ramp in CVRM outcome trials. AI tools include IDA, which could halve time-to-scale-up in synthetic drug processes, and QCS, a computational pathology system refining patient selection for antibody-drug conjugates. The acquisition of Modela AI is expected to bolster AstraZeneca’s pathology foundation models.

Management reiterated confidence in its $80 billion revenue ambition for 2030, noting consensus estimates have risen from $67 billion when announced to around $80 billion today. In oncology, underappreciated assets include the dual CD19/BCMA CAR-T AZD0120 and the PD-1/TIGIT bispecific rilvegostomig, while lifecycle management of Tagrisso is bolstered by combination data. On U.S. policy, the phased Most Favored Nation agreement is expected to affect low-single-digit percentages of global sales in Medicaid. Key 2026 catalysts span Phase III readouts in non–small cell lung cancer (datopotamab deruxtecan), additional Imfinzi data in bladder cancer and early HCC, camizestrant in first-line breast cancer, Wainua in ATTR cardiomyopathy, tozorakimab in COPD, and rare-disease readouts for Ultomiris and asfotase alfa.